Newsletter

Charlie Youlden

Charlie is an Associate Equity Research Analyst covering ASX small caps across technology, mining and industrials.

His investing journey began in 2020 with large-cap US technology stocks, before he went on to complete a Commerce degree in Finance and Marketing at UTS, the Wall Street Prep Financial Modelling course, and Columbia Business School’s Value Investing course.

Charlie’s goal is to make investing clear, digestible and genuinely useful for everyday retail investors, helping them make better decisions with more confidence.

984 articles published

Tech Stocks Technology

Objective’s Results Spark 19% Gains, but Is the Growth Just Beginning?

Objective Hits Record Highs as Recurring Revenue Powers Growth Objective Corporation (ASX:OCL) gave investors plenty to celebrate after its 2025 full-year results sent the stock up 19 percent to fresh all-time highs. For patient shareholders, the rally capped an impressive 80 percent return over the past year. The company has been steadily reshaping itself into…

ByCharlie YouldenAugust 21, 20250Comments

Tech Stocks Technology

Why Did Megaport Drop 18% After Strong Results?

Megaport’s Strong Results Met With a Sharp Sell-Off Megaport (ASX:MP1) caught investors off guard this reporting season. Despite delivering strong results, its share price slid 18 percent in a single session. For a company riding the artificial intelligence boom and positioning itself as a leader in Network as a Service, that kind of drop was…

ByCharlie YouldenAugust 21, 20250Comments

Healthcare Stocks

Is the Market Missing Telix’s Long-Term Potential after 63% Revenue Growth?

Telix Pharmaceuticals: Controversy, Growth, and the Road Ahead Every investor knows the uneasy feeling of watching a stock fall, not because of poor earnings, but because of controversy. That is the position Telix Pharmaceuticals (ASX: TLX) finds itself in today. After headlines about an FDA subpoena related to how it communicated drug progress to investors,…

ByCharlie YouldenAugust 21, 20250Comments

Healthcare Stocks

Argent BioPharma Jumps 86% After Bold AusCann Acquisition

Argent BioPharma Expands with AusCann Deal On August 19, Argent BioPharma (ASX: RGT) announced it was buying AusCann’s assets, which include the 100% ownership of the Neuvis drug delivery platform, 48% of CannPal Animal Therapeutics, and part of 20% of ECC Pharm. This deal gives Argent new technology, more research data, and access to the…

ByCharlie YouldenAugust 19, 20250Comments

Mining Stocks

Magnetite Mines Surges 181%: Is Ironback Hill the Next Rare Earth Breakthrough?

Rarely does a stock surge 181% overnight on the back of old drill samples. That’s exactly what happened when Magnetite Mines (ASX: MGT) jolted the ASX with news of rare earths mineralisation at its Ironback Hill Project in South Australia. For years, this ground was known mainly for iron ore. But by re-testing archived drilling…

ByCharlie YouldenAugust 19, 20250Comments

Tech Stocks

Nvidia (NSDQ: NVDA) Earnings: Can the AI Giant Keep Beating Wall Street?

Nvidia Q2 Preview: Can the AI Leader Keep Beating Expectations? For the past two years, Nvidia (NSDQ: NVDA) has delivered quarter after quarter of revenue and earnings beats, yet analysts remain convinced there is still more to come. Ahead of the upcoming Q2 results, investment banks including Morgan Stanley, Cantor Fitzgerald, and Mizuho have all…

ByCharlie YouldenAugust 19, 20250Comments

Blue Chip Stocks Healthcare Stocks

CSL FY25 Analysis 14% Profit Growth Despite Slower Revenue Growth

CSL’s Growth Slows, Profits Surge: What Investors Need to Know For decades, CSL Limited (ASX: CSL) has been regarded as one of Australia’s most dependable healthcare giants, the kind of stock you could tuck away and forget. Yet in recent years, even this blue-chip defensive stock has shown it is not immune to market turbulence.…

ByCharlie YouldenAugust 19, 20250Comments

Mining Stocks

Why Dateline Resources (ASX: DTR) Is on Investor Watchlists After a 3,000% Rally

Dateline Resources (ASX: DTR) Holds 1M+ Oz Gold and Possible REE Upside It is not often you find a project sitting on over a million ounces of gold in the ground and potentially rare earth elements right next door to one of the world’s largest REE mines. The Colosseum Gold–REE Project 100% owned by Dateline…

ByCharlie YouldenAugust 14, 20250Comments

Bank Stocks Blue Chip Stocks

Why Commonwealth Bank (ASX:CBA) Stock Lost $15 Billion Overnight. What Investors Should Watch Next

CBA’s $15 Billion Wake-Up Call On the ASX, $15 billion can disappear in a single day, and that is exactly what happened to Commonwealth Bank (ASX: CBA) this week after releasing its 2025 results. It was not a profit warning, nor a shock loss. In fact, the numbers were strong. But in markets, strength can…

ByCharlie YouldenAugust 14, 20250Comments

Semiconductor stocks Tech Stocks Technology Uncategorized

Why Investors Are Watching Archer Materials After a 35% Surge

What if diagnosing a serious disease was as simple as taking a home pregnancy test? Right now, in Adelaide, a small-cap tech company, Archer Materials (ASX:AXE), is working to make that possible. Their goal is to shrink an entire medical lab onto a semiconductor chip that can analyse a drop of bodily fluid and detect…

ByCharlie YouldenAugust 14, 20250Comments